Several other research analysts also recently weighed in on the stock. StockNews.com assumed coverage on shares of Viking Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research downgraded shares of Viking Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 7th. Finally, Raymond James decreased their price target on shares of Viking Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, February 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.31.
Viking Therapeutics stock opened at $2.20 on Thursday. The stock’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $4.28. The stock has a market cap of $170.22 million, a price-to-earnings ratio of -3.06 and a beta of 1.67. Viking Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $7.20.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Lindbrook Capital LLC raised its position in shares of Viking Therapeutics by 1,062.8% during the 4th quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 6,855 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $51,000. Fox Run Management L.L.C. purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $52,000. Finally, Virtu Financial LLC purchased a new stake in Viking Therapeutics in the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.
Viking Therapeutics Company Profile (Get Rating)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- Get a free copy of the StockNews.com research report on Viking Therapeutics (VKTX)
- Harley-Davidson Skids Into A Buying Opportunity
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.